Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study
Authors' conclusion
Over the past decade, substantial changes in incident GLD prescribing have occurred in Australia. While metformin continues to play a central role as initial treatment, major shifts toward use of initial dual therapy, including SGLT2i and GLP-1RA, have occurred.
Study context
- Population
- Individuals initiating glucose lowering drug (GLDs) in Australia, Pharmaceutical Benefits Scheme (PBS) data 2014–2024
- Participants
- 49,129 individuals
- Exposure
- Incident GLD initiation in 2014 vs 2024
- Outcome
- Proportions of incident monotherapy, dual therapy and triple therapy
- Follow-up
- 2014 to 2024
Methodological details10% PBS dataset
- 10% PBS dataset
Main finding
As reported in the abstract
Incident GLD monotherapy
Observational data: associations, not effects.
Further findings
Incident dual therapy
Incident triple therapy
Overall incident metformin (monotherapy or combination)
Incident metformin monotherapy
Incident SGLT2i and GLP-1 RA (monotherapy or combination) · 2024
- Incident SGLT2i
- 35.7%
- Incident GLP-1 RA
- 11.2%
Age at incident prescribing · 2014 to 2024
- Age at incident prescribing increased for all GLD classes except GLP-1 RA, which decreased
Original publication
Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study. Diabetes Obes Metab. Published 29 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →